Mechanisms of thrombocytopenia induced by interferon therapy for chronic hepatitis B

[Guest guest]

http://www.springerlink.com/content/93365n74k8871163/

Mechanisms of thrombocytopenia induced by interferon therapy for chronic

hepatitis B

Journal Journal of Gastroenterology

Publisher Springer Japan

ISSN 0944-1174 (Print) 1435-5922 (Online)

Issue Volume 32, Number 2 / March, 1997

Category Liver, Pancreas, and Biliary Tract

DOI 10.1007/BF02936369

Pages 206-210

Liver, Pancreas, and Biliary Tract

Mechanisms of thrombocytopenia induced by interferon therapy for chronic

hepatitis B

Michio Sata1 , Yoichi Yano1, Yasutsugu Yoshiyama1, Tatsuya Ide1, Ryukichi

Kumashiro1, Hiroshi Suzuki1 and Kyuichi Tanikawa1

(1) Second Department of Medicine, Kurume University School of Medicine, 67

Asahi-machi, 830 Kurume, Fukuoka, Japan

Received: 19 April 1996 Accepted: 30 August 1996

Abstract To clarify the mechanisms of thrombocytopenia observed in patients

with chronic hepatitis B treated with interferon. We studied six patients with

chronic active hepatitis B who received intramuscular injections of natural

interferon-alpha (3 or 5 million IU/day) for 4 weeks. Peripheral blood platelet

counts, bone marrow findings, and platelet kinetics, determined

using111In-labeled platelets, were analyzed. Platelets decreased significantly 1

week after the beginning of treatment and remained decreased until the

completion of treatment. The number of nucleated cells and megakaryocytes in

bone marrow decreased in three of five patients studied during treatment. The

kinetic study showed platelet survival time to be 8.1±1.3 days (range,

5.8–10.0). One day after platelet injection, platelets accumulated predominantly

in the splenic area in all patients, whereas hepatic accumulation was

predominant 7 days after injection in three of the six patients.

Thrombocytopenia during interferon treatment arises from the inhibition of stem

cell proliferation and differentiation in the bone marrow and from the capture

of platelets by the liver.

[Guest guest]

http://www.springerlink.com/content/93365n74k8871163/

Mechanisms of thrombocytopenia induced by interferon therapy for chronic

hepatitis B

Journal Journal of Gastroenterology

Publisher Springer Japan

ISSN 0944-1174 (Print) 1435-5922 (Online)

Issue Volume 32, Number 2 / March, 1997

Category Liver, Pancreas, and Biliary Tract

DOI 10.1007/BF02936369

Pages 206-210

Liver, Pancreas, and Biliary Tract

Mechanisms of thrombocytopenia induced by interferon therapy for chronic

hepatitis B

Michio Sata1 , Yoichi Yano1, Yasutsugu Yoshiyama1, Tatsuya Ide1, Ryukichi

Kumashiro1, Hiroshi Suzuki1 and Kyuichi Tanikawa1

(1) Second Department of Medicine, Kurume University School of Medicine, 67

Asahi-machi, 830 Kurume, Fukuoka, Japan

Received: 19 April 1996 Accepted: 30 August 1996

Abstract To clarify the mechanisms of thrombocytopenia observed in patients

with chronic hepatitis B treated with interferon. We studied six patients with

chronic active hepatitis B who received intramuscular injections of natural

interferon-alpha (3 or 5 million IU/day) for 4 weeks. Peripheral blood platelet

counts, bone marrow findings, and platelet kinetics, determined

using111In-labeled platelets, were analyzed. Platelets decreased significantly 1

week after the beginning of treatment and remained decreased until the

completion of treatment. The number of nucleated cells and megakaryocytes in

bone marrow decreased in three of five patients studied during treatment. The

kinetic study showed platelet survival time to be 8.1±1.3 days (range,

5.8–10.0). One day after platelet injection, platelets accumulated predominantly

in the splenic area in all patients, whereas hepatic accumulation was

predominant 7 days after injection in three of the six patients.

Thrombocytopenia during interferon treatment arises from the inhibition of stem

cell proliferation and differentiation in the bone marrow and from the capture

of platelets by the liver.

[Guest guest]

http://www.springerlink.com/content/93365n74k8871163/

Mechanisms of thrombocytopenia induced by interferon therapy for chronic

hepatitis B

Journal Journal of Gastroenterology

Publisher Springer Japan

ISSN 0944-1174 (Print) 1435-5922 (Online)

Issue Volume 32, Number 2 / March, 1997

Category Liver, Pancreas, and Biliary Tract

DOI 10.1007/BF02936369

Pages 206-210

Liver, Pancreas, and Biliary Tract

Mechanisms of thrombocytopenia induced by interferon therapy for chronic

hepatitis B

Michio Sata1 , Yoichi Yano1, Yasutsugu Yoshiyama1, Tatsuya Ide1, Ryukichi

Kumashiro1, Hiroshi Suzuki1 and Kyuichi Tanikawa1

(1) Second Department of Medicine, Kurume University School of Medicine, 67

Asahi-machi, 830 Kurume, Fukuoka, Japan

Received: 19 April 1996 Accepted: 30 August 1996

Abstract To clarify the mechanisms of thrombocytopenia observed in patients

with chronic hepatitis B treated with interferon. We studied six patients with

chronic active hepatitis B who received intramuscular injections of natural

interferon-alpha (3 or 5 million IU/day) for 4 weeks. Peripheral blood platelet

counts, bone marrow findings, and platelet kinetics, determined

using111In-labeled platelets, were analyzed. Platelets decreased significantly 1

week after the beginning of treatment and remained decreased until the

completion of treatment. The number of nucleated cells and megakaryocytes in

bone marrow decreased in three of five patients studied during treatment. The

kinetic study showed platelet survival time to be 8.1±1.3 days (range,

5.8–10.0). One day after platelet injection, platelets accumulated predominantly

in the splenic area in all patients, whereas hepatic accumulation was

predominant 7 days after injection in three of the six patients.

Thrombocytopenia during interferon treatment arises from the inhibition of stem

cell proliferation and differentiation in the bone marrow and from the capture

of platelets by the liver.

[Guest guest]

http://www.springerlink.com/content/93365n74k8871163/

Mechanisms of thrombocytopenia induced by interferon therapy for chronic

hepatitis B

Journal Journal of Gastroenterology

Publisher Springer Japan

ISSN 0944-1174 (Print) 1435-5922 (Online)

Issue Volume 32, Number 2 / March, 1997

Category Liver, Pancreas, and Biliary Tract

DOI 10.1007/BF02936369

Pages 206-210

Liver, Pancreas, and Biliary Tract

Mechanisms of thrombocytopenia induced by interferon therapy for chronic

hepatitis B

Michio Sata1 , Yoichi Yano1, Yasutsugu Yoshiyama1, Tatsuya Ide1, Ryukichi

Kumashiro1, Hiroshi Suzuki1 and Kyuichi Tanikawa1

(1) Second Department of Medicine, Kurume University School of Medicine, 67

Asahi-machi, 830 Kurume, Fukuoka, Japan

Received: 19 April 1996 Accepted: 30 August 1996

Abstract To clarify the mechanisms of thrombocytopenia observed in patients

with chronic hepatitis B treated with interferon. We studied six patients with

chronic active hepatitis B who received intramuscular injections of natural

interferon-alpha (3 or 5 million IU/day) for 4 weeks. Peripheral blood platelet

counts, bone marrow findings, and platelet kinetics, determined

using111In-labeled platelets, were analyzed. Platelets decreased significantly 1

week after the beginning of treatment and remained decreased until the

completion of treatment. The number of nucleated cells and megakaryocytes in

bone marrow decreased in three of five patients studied during treatment. The

kinetic study showed platelet survival time to be 8.1±1.3 days (range,

5.8–10.0). One day after platelet injection, platelets accumulated predominantly

in the splenic area in all patients, whereas hepatic accumulation was

predominant 7 days after injection in three of the six patients.

Thrombocytopenia during interferon treatment arises from the inhibition of stem

cell proliferation and differentiation in the bone marrow and from the capture

of platelets by the liver.